MDLinxWhat the New Findings About Gabapentin Could Mean For Your Practice in 2026

Six or more gabapentin prescriptions linked to 29% increased dementia risk and 85% increased mild cognitive impairment risk, but experts warn study shows only association, not causation. Prescriptions more than doubled from 2010-2024 as physicians shifted from opioids to alternatives for chronic pain management.

⚖️ PROFESSIONAL IMPACT

• Study couldn’t control for dose, duration, pain severity, or healthcare utilization, all of which independently increase dementia risk in chronic pain patients
• Absolute risk remains low: approximately 1 additional dementia diagnosis per 100 patients over 10 years in highest-risk subgroups
• Non-elderly adults (18-64) showed twice the dementia risk with gabapentin use, suggesting age-specific vulnerability patterns requiring study
• Findings create prescribing uncertainty for most common alternative to opioids in neuropathic pain management with limited therapeutic substitutes

🎯 ACTION ITEMS

• Reassess cognitive function at routine intervals in patients on chronic gabapentin therapy
• Document baseline cognitive status before initiating gabapentin in patients under 65
• Reduce doses in renal impairment to prevent accumulation and cognitive side effects
• Consider nonpharmacologic therapies as first-line before gabapentin in patients with existing cognitive impairment

Gabapentin-Related Reading